Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab emtansine extension study in previously treated HER2-positive metastatic cancer
2010-021067-32Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2011
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab emtansine in cancer (2 arms), sponsored by Roche. Primary endpoint: Incidence of adverse events leading to trastuzumab emtansine or combination treatment discontinuation or dose reduction. Started Mar 2011; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
cancer
Beyond the preview
Go deeper on 2010-021067-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021067-32.